Literature DB >> 9288767

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

P Guldberg1, P thor Straten, A Birck, V Ahrenkiel, A F Kirkin, J Zeuthen.   

Abstract

The MMAC1/PTEN gene, located at 10q23.3, is a candidate tumor suppressor commonly mutated in glioma. We have studied the pattern of deletion, mutation, and expression of MMAC1/PTEN in 35 unrelated melanoma cell lines. Nine (26%) of the cell lines showed partial or complete homozygous deletion of the MMAC1/PTEN gene, and another six (17%) harbored a mutation in combination with loss of the second allele. Mutations could also be demonstrated in uncultured tumor specimens from which the cell lines had been established, and cell lines derived from two different metastases from one individual carried the same missense mutation. Collectively, these findings suggest that disruption of MMAC1/PTEN by allelic loss or mutation may contribute to the pathogenesis or neoplastic evolution in a large proportion of malignant melanomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  116 in total

1.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Region-specific transcriptional response to chronic nicotine in rat brain.

Authors:  J K Kane; T Barrett; M P Vawter; R Chang; J Z Ma; D M Donovan; B Sharp; K G Becker; M D Li
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

3.  Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p.

Authors:  Z Adám; R Adány; A Ladányi; J Tímár; M Balázs
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 5.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 6.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

7.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  S Ramaswamy; N Nakamura; F Vazquez; D B Batt; S Perera; T M Roberts; W R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 8.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 9.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

10.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.